• Ultrasound guidance may lead to a higher first-attempt success rate and improved time to successful common femoral artery (CFA) access, while reducing the venipuncture rate (unintentionally ...

Merit Medical Systems MMSI released 12-month efficacy results for its WRAPSODY Cell-Impermeable Endoprosthesis (“CIE”), ...

Systems announced that the six-month results from the randomized arm of the WRAPSODY Arteriovenous Access Efficacy trial ...

Merit Medical Systems, Inc. announced the publication of the 6-month results from the randomized arm of the WAVE trial of arterio ...

At 6 months, the WRAPSODY CIE achieved 89.8% and 72.6% target lesion primary patency and access circuit primary patency, respectively.At 12 months, the WRAPSODY CIE achieved 70.1% and 58.1% target ...

A 20-year-old male presented with seizures and was diagnosed with left parietal arteriovenous malformation combined with developmental venous anomaly in the left frontal lobe, with the draining veins ...

March 14, 2025—VentureMed Group, Inc., a medical device company focused on arteriovenous access and peripheral arterial disease, recently announced the appointment of Jordan Knepper, MD, as Chief ...

In this study, we successfully established a stable method for the isolation of endothelial cells (ECs) from human cerebral arteriovenous malformation (cAVM) tissues. Despite human cAVM tissues having ...